Brief: Royalty Pharma Raises Full-Year 2023 Guidance

Royalty Pharma

15/03/2023 12:04

March 15 (Reuters) - Royalty Pharma PLC  RPRX.O :
    * ROYALTY PHARMA RAISES FULL YEAR 2023 GUIDANCE
    * ROYALTY PHARMA - SEES 2023 ADJUSTED CASH RECEIPTS
(NON-GAAP) TO
BE BETWEEN $2,850 MILLION & $2,950 MILLION, EXCLUDING
CONTRIBUTIONS FROM FUTURE TRANSACTIONS
    * ROYALTY PHARMA  - WILL NOW RECEIVE ROYALTIES ON NET SALES
OF
BOTH NURTEC ODT AND ZAVZPRET

Source text for Eikon:  ID:nGNXb9x87q 
Further company coverage:  RPRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))